Health In Tech Inc. Reports 86% YoY Revenue Increase for Q2 2025; Adjusted EBITDA Up 134%

Reuters
22 Jul
Health In Tech Inc. Reports 86% YoY Revenue Increase for <a href="https://laohu8.com/S/QTWO">Q2</a> 2025; Adjusted EBITDA Up 134%

Health In Tech Inc. (Nasdaq: HIT) has reported its financial results for the second quarter of 2025, showing significant growth. The company's revenues reached $9.3 million, an 86% increase year over year. For the first half of 2025, revenues were $17.3 million, which represents 89% of the total for the full year 2024. The company also reported an adjusted EBITDA of $1.6 million for the quarter, marking a 134% increase compared to the previous year. The first-half adjusted EBITDA was $2.8 million, 1.2 times the full year 2024 result. Health In Tech's cash balance stands at $8.1 million. The number of billed enrolled employees increased by 5,738 year over year, totaling 24,839. The company continues to focus on strategic expansion of its distribution network and customer acquisition, supported by its strong cash position.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Health in Tech Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN34117) on July 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10